Drug Profile

SAM 101

Alternative Names: Antipsychotics/minocycline; Minocycline/antipsychotics; SAM-101

Latest Information Update: 07 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MinoGuard
Class Antipsychotics; Neuropsychotherapeutics; Small molecules; Tetracyclines
Mechanism of Action Protein 30S ribosomal subunit inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Schizophrenia

Highest Development Phases

Discontinued Schizophrenia

Most Recent Events

31 Jan 2014 Phase II development is ongoing in Israel, UK and Japan
30 Nov 2011 MinoGuard has been acquired by XTL Biopharmaceuticals
25 Mar 2011 XTL Biopharmaceuticals agrees to acquire MinoGuard

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com